FDA Approves New Juvéderm Cosmetic Drug

August 3, 2022

The FDA has approved Juvéderm® Volux™ XC (hyaluronic acid) to improve moderate to severe loss of jawline definition in adults older than 21 years.

The product is the newest addition to the Juvéderm line of injectable gels for cosmetic use made by Allergan Juvéderm injectable gels treat wrinkles and lines in cheeks, chin, lips, and undereye hollows.
Juvéderm Volux XC is administered via deep injection by a trained healthcare professional. The manufacturer plans to launch healthcare provider training in the fall of 2022, with wider product distribution expected in 2023.

Related News

About 6% of U.S. Adults Have ADHD, Drug Shortages Are Affecting Treatment

October 10, 2024

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager

By submitting this form, you are consenting to receive marketing emails from: Benecard Services, LLC. (Lawrenceville, NJ 08648), https://www.benecard.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact.

FDA Approves New Juvéderm Cosmetic Drug

August 3, 2022

Related News

About 6% of U.S. Adults Have ADHD, Drug Shortages Are Affecting Treatment

OTULFI™

FLYRCADO

Benefit Advisors & Employees - Want to know more?

Benecard

Newsletter